These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

458 related items for PubMed ID: 18931828

  • 1. Long-term safety and tolerability of epoetin zeta, administered intravenously, for maintenance treatment of renal anemia.
    Baldamus C, Krivoshiev S, Wolf-Pflugmann M, Siebert-Weigel M, Koytchev R, Bronn A.
    Adv Ther; 2008 Nov; 25(11):1215-28. PubMed ID: 18931828
    [Abstract] [Full Text] [Related]

  • 2. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
    Wizemann V, Rutkowski B, Baldamus C, Scigalla P, Koytchev R, Epoetin Zeta Study Group.
    Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
    [Abstract] [Full Text] [Related]

  • 3. Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia.
    Krivoshiev S, Wizemann V, Czekalski S, Schiller A, Pljesa S, Wolf-Pflugmann M, Siebert-Weigel M, Koytchev R, Bronn A, Epoetin Zeta Study Group.
    Adv Ther; 2010 Feb; 27(2):105-17. PubMed ID: 20369312
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
    Besarab A, Salifu MO, Lunde NM, Bansal V, Fishbane S, Dougherty FC, Beyer U, Ba16285 Study Investigators.
    Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
    [Abstract] [Full Text] [Related]

  • 5. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
    Sulowicz W, Locatelli F, Ryckelynck JP, Balla J, Csiky B, Harris K, Ehrhard P, Beyer U, PROTOS Study Investigators.
    Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
    [Abstract] [Full Text] [Related]

  • 6. Therapeutic equivalence, long-term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis.
    Haag-Weber M, Vetter A, Thyroff-Friesinger U, INJ-Study Group.
    Clin Nephrol; 2009 Nov; 72(5):380-90. PubMed ID: 19863881
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Switching epoetin alfa and epoetin zeta in patients with renal anemia on dialysis: Posthoc analysis.
    Więcek A, Ahmed I, Scigalla P, Koytchev R.
    Adv Ther; 2010 Dec; 27(12):941-52. PubMed ID: 20972656
    [Abstract] [Full Text] [Related]

  • 13. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
    Voravud N, Sriuranpong V.
    J Med Assoc Thai; 2005 May; 88(5):607-12. PubMed ID: 16149676
    [Abstract] [Full Text] [Related]

  • 14. Comparison of the therapeutic efficacy of epoetin beta and epoetin alfa in maintenance phase hemodialysis patients.
    Loughnan A, Ali GR, Abeygunasekara SC.
    Ren Fail; 2011 May; 33(3):373-5. PubMed ID: 21401367
    [Abstract] [Full Text] [Related]

  • 15. Therapeutic effects of epoetin zeta in the treatment of chemotherapy-induced anaemia.
    Tzekova V, Mihaylov G, Elezovic I, Koytchev R, Epoetin Zeta Oncology Study Group.
    Curr Med Res Opin; 2009 Jul; 25(7):1689-97. PubMed ID: 19505200
    [Abstract] [Full Text] [Related]

  • 16. Effect of epoetin zeta for correction of renal anemia in hemodialysis patients with thalassemia minor.
    Kumchev E, Koytchev R, Dimitrakov D, Stavrev P, Tsochev G, Siebert-Weigel M.
    Adv Ther; 2008 Dec; 25(12):1375-8. PubMed ID: 19043680
    [Abstract] [Full Text] [Related]

  • 17. Comparison of two epoetin brands in anemic hemodialysis patients: results of two efficacy trials and a single-dose pharmacokinetic study.
    Milutinović S, Plavljanić E, Trkulja V.
    Fundam Clin Pharmacol; 2006 Oct; 20(5):493-502. PubMed ID: 16968421
    [Abstract] [Full Text] [Related]

  • 18. Randomized trial on the therapeutic equivalence between Eprex and GerEPO in patients on haemodialysis.
    Goh BL, Ong LM, Sivanandam S, Lim TO, Morad Z, Biogeneric EPO Study Group.
    Nephrology (Carlton); 2007 Oct; 12(5):431-6. PubMed ID: 17803464
    [Abstract] [Full Text] [Related]

  • 19. Epoetin omega for treatment of anemia in maintenance hemodialysis patients.
    Sikole A, Spasovski G, Zafirov D, Polenakovic M.
    Clin Nephrol; 2002 Mar; 57(3):237-45. PubMed ID: 11924756
    [Abstract] [Full Text] [Related]

  • 20. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients.
    Kaufman JS, Reda DJ, Fye CL, Goldfarb DS, Henderson WG, Kleinman JG, Vaamonde CA.
    N Engl J Med; 1998 Aug 27; 339(9):578-83. PubMed ID: 9718376
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.